Study points to a new, effective treatment option for patients with mesothelioma

Combining the immunotherapy agent durvalumab with the chemotherapy agents pemetrexed and cisplatin or carboplatin may provide a new treatment option for patients who have inoperable pleural mesothelioma, a cancer of the tissues lining the lungs, according to a phase II clinical trial led by researchers at the Johns Hopkins Kimmel Cancer Center and the Bloomberg~Kimmel Institute for Cancer Immunotherapy.